{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:18:21Z","timestamp":1788157101077,"version":"build-2803163510"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Pers. Med.","JPM"],"abstract":"<jats:p>Molecular residual disease (MRD) testing approaches with plasma next-generation sequencing (NGS) testing to identify circulating tumor DNA (ctDNA) in resectable-stage non-small cell lung cancer (NSCLC) are evolving. The MRD concept is to better guide perioperative systemic treatment and identify recurrent NSCLC before symptomatic radiographic recurrences. Multiple tumor-informed assays are available with technology driving lower levels of ctDNA detection. However, it remains unclear that individual patients derive survival outcome benefit from MRD testing. NSCLC tumor biology of spatial heterogeneity, early parallel metastases, and recurrence clonal evolution can impact tumor-informed approaches irrespective of specific assay level of ctDNA detection. Clinical decision making guided by tumor-informed MRD testing to date have been limited by recurrence risks of up to 20% when landmark MRD-negative, improved outcomes benefit of adjuvant treatment even when landmark MRD-negative, and lead times with longitudinal MRD-positive conversion of several months or longer before overt radiographic recurrences with no proven strategy of survival benefit with intervening treatment. Cautionary tumor biology and clinical issues remain in the clinical utility of tumor-informed MRD testing in resected NSCLC. These need to be clarified with certainty before MRD testing should step beyond a technology-driven prognostic recurrence risk indicator before becoming an absolute clinical guide to meaningfully impact individual patient management and outcomes.<\/jats:p>","DOI":"10.3390\/jpm16090454","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:55:56Z","timestamp":1788155756000},"page":"454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6610-5292","authenticated-orcid":false,"given":"Paul R.","family":"Walker","sequence":"first","affiliation":[{"name":"Emeritus Faculty, Division of Hematology\/Oncology, Brody School of Medicine at East Carolina University, Greenville, NC 27834, USA"},{"name":"Circulogene, Pensacola, FL 32502, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumors","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/OTT.S322242","article-title":"Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions","volume":"16","author":"Feber","year":"2023","journal-title":"OncoTargets Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor Heterogeneity: Evolution through Space and Time","volume":"72","author":"Swanton","year":"2012","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/JTO.0b013e3181a94af4","article-title":"Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer","volume":"4","author":"Park","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2017.07.019","article-title":"High-depth sequencing of paired primary and metastatic tumors: Implications for personalized medicine","volume":"84","author":"Grellety","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical Implications of Plasma-Based Genotyping with the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/PO.20.00241","article-title":"Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in advanced Non-Small-Cell Lung Cancer","volume":"5","author":"Palmero","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)","volume":"24","author":"Raez","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-20-3444","article-title":"Tumor Tissue-Versus Plasma-Based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer","volume":"27","author":"Vidula","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","article-title":"Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort","volume":"1","author":"Iams","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-25-0430","article-title":"The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME trial","volume":"32","author":"Botticelli","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/2159-8290.CD-25-0164","article-title":"From Discovery to Diagnosis: A Perspective from Circulating Tumor Cells in Personalized Oncology","volume":"15","author":"Pantel","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.7150\/thno.34337","article-title":"Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity","volume":"9","author":"Heymann","year":"2019","journal-title":"Theranostics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.omto.2019.08.006","article-title":"The Discordance of Gene Mutations Between Circulating Tumor Cells and Primary\/Metastatic Tumor","volume":"15","author":"Wang","year":"2019","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2014.58.8293","article-title":"Intratumoral Heterogeneity of ALK-Rearranged and ALK\/EGFR Coaltered Lung Adenocarcinoma","volume":"33","author":"Cai","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"346","author":"Bruin","year":"2014","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.aaf2784","article-title":"Metastasis as an evolutionary process","volume":"352","author":"Turajlic","year":"2016","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc2627","article-title":"Parallel progression of primary tumors and metastases","volume":"9","author":"Klein","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non-Small-Cell Lung Cancer","volume":"376","author":"Wilson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Huebner","year":"2023","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","article-title":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","volume":"52","author":"Hu","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jtho.2018.07.101","article-title":"The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer","volume":"13","author":"Rozenblum","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2500489","DOI":"10.1200\/PO-25-00489","article-title":"Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2300132","DOI":"10.1200\/PO.23.00132","article-title":"Clonal hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface","volume":"7","author":"Buttigieg","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-24-2909","article-title":"Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.annonc.2024.12.006","article-title":"Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: Unraveling the optimal strategy","volume":"36","author":"Camblor","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_40","first-page":"100762","article-title":"Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients with Lung Cancer with a Long Follow-Up Data: An Exploratory Study","volume":"6","author":"Ohara","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/PO.19.00204","article-title":"Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients with Advanced Cancers","volume":"4","author":"Vu","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/s41591-022-02068-8","article-title":"Circulating tumor DNA as a novel prognostic indicator","volume":"28","author":"Vivancos","year":"2022","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41568-024-00752-0","article-title":"Cancer-induced systemic pre-conditioning of distant organs: Building a niche for metastatic cells","volume":"25","author":"Rabas","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cui, Q., Zhang, J.-T., Yin, H., Zhang, K.-P., Xu, J., Xu, F.-P., Zhong, W.-Z., Wu, Y.-L., and Zhang, Q.-L. (2026). Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer. J. Thorac. Oncol., in press.","DOI":"10.1016\/j.jtho.2026.104090"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): An interim analysis of a randomized, triple-blind, phase 3 trial","volume":"23","author":"Marreaud","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2026.8992","article-title":"Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer","volume":"336","author":"Chaft","year":"2026","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO-25-01828","article-title":"Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer","volume":"44","author":"Goss","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.athoracsur.2024.01.004","article-title":"Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer","volume":"118","author":"Martins","year":"2024","journal-title":"Ann. Thorac. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S779","DOI":"10.1016\/j.annonc.2024.08.1270","article-title":"IMpower010: ctDNA status and 5y DFS follow up in patients with resected NSCLC who received adjuvant chemotherapy followed by atezolizumab or best supportive care","volume":"8","author":"Wakelee","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S1239","DOI":"10.1016\/j.annonc.2024.08.2290","article-title":"LBA49 Associations of ctDNA clearance during neoadjuvant Tx with pathological response and event-free survival in pts with resectable NSCLC: Expanded analysis from AEGEAN","volume":"35","author":"Reck","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2025.43.16_suppl.8009","article-title":"Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial","volume":"43","author":"Reck","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1158\/1078-0432.CCR-25-2958","article-title":"Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer","volume":"32","author":"Provencio","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/2159-8290.CD-25-0375","article-title":"Detection of Cancers Three Years Prior to Diagnosis Using Plasma Cell-Free DNA","volume":"15","author":"Wang","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2026.44.16_suppl.8017","article-title":"Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non-small cell lung cancer","volume":"44","author":"Black","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(22)00451-X","article-title":"Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): A multicentre, open-label, randomized, phase 3 trial","volume":"23","author":"Westeel","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"djx029","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized Trial Comparing a Web-Mediated Follow-Up with Routine Surveillance in Lung Cancer Patients","volume":"109","author":"Denis","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2300191","DOI":"10.1200\/PO.23.00191","article-title":"Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"7","author":"Aggarwal","year":"2023","journal-title":"JCO Precis. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/9\/454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:09:24Z","timestamp":1788156564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/9\/454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jpm16090454"],"URL":"https:\/\/doi.org\/10.3390\/jpm16090454","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}